Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
Kaiser Permanente
Accent Therapeutics
Duke University
A2 Biotherapeutics Inc.
Arvinas Inc.
Zhejiang University
National Institutes of Health Clinical Center (CC)
University of Colorado, Denver
Unity Health Toronto
GlaxoSmithKline
Pheon Therapeutics
Colorado State University
Orano Med LLC
Novartis
National Institutes of Health Clinical Center (CC)
Institut du Cancer de Montpellier - Val d'Aurelle
Massachusetts General Hospital
University of Pittsburgh
Tempus AI
UNC Lineberger Comprehensive Cancer Center
New Mexico Cancer Research Alliance
Sahlgrenska University Hospital
Elicio Therapeutics
Institut Bergonié
GONGCHU Biotechnology Co., Ltd
Palleon Pharmaceuticals, Inc.
Jonsson Comprehensive Cancer Center
Novita Pharmaceuticals, Inc.
ModeX Therapeutics, An OPKO Health Company
University of Alabama at Birmingham
Compugen Ltd
Memorial Sloan Kettering Cancer Center
Stanford University
Mayo Clinic
Universitat Jaume I
Stanford University
Universidade Federal de Pernambuco
Compugen Ltd
NextCure, Inc.
Catharina Ziekenhuis Eindhoven
Revolution Medicines, Inc.
Washington University School of Medicine
Hospital Universitario de Fuenlabrada
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NantCell, Inc.
NextCure, Inc.